ERBB2 and cancer: In LN+ER/PR-Her2+ status group, the level of serum sCD14 was significantly lower in patients with recurrence in 3 years than those without recurrence (Figure 3A), and was significantly correlated to the risk of 3-year cancer recurrence as well.